Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 1
1996 3
1997 23
1998 64
1999 66
2000 70
2001 70
2002 81
2003 105
2004 128
2005 96
2006 120
2007 102
2008 101
2009 99
2010 111
2011 95
2012 100
2013 102
2014 109
2015 119
2016 118
2017 133
2018 122
2019 105
2020 143
2021 139
2022 163
2023 187
2024 191
2025 177
2026 95

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,055 results

Results by year

Filters applied: . Clear all
Page 1
Cholinesterase inhibitors for Alzheimer's disease.
Birks J. Birks J. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593. Cochrane Database Syst Rev. 2006. PMID: 16437532 Free PMC article.
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). ...Fewer patients suffer adv …
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of eac …
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. ...The ChE-Is currently available in the market are donepezil, riv …
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive declin …
Alzheimer's disease.
Blennow K, de Leon MJ, Zetterberg H. Blennow K, et al. Lancet. 2006 Jul 29;368(9533):387-403. doi: 10.1016/S0140-6736(06)69113-7. Lancet. 2006. PMID: 16876668 Review.
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease--ie, plaques, composed of amyloid beta (Abeta), and tangles, composed o …
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding …
Donepezil for dementia due to Alzheimer's disease.
Birks J, Harvey RJ. Birks J, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. doi: 10.1002/14651858.CD001190.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2018 Jun 18;6:CD001190. doi: 10.1002/14651858.CD001190.pub3. PMID: 16437430 Updated.
OBJECTIVES: The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due to Alzheimer's disease. ...AUTHORS' CONCLUSIONS: People with mild, moderate or severe dementia due to Alzheim …
OBJECTIVES: The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due …
Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.
Chen Y, Lai M, Tao M. Chen Y, et al. Medicine (Baltimore). 2024 Apr 19;103(16):e37799. doi: 10.1097/MD.0000000000037799. Medicine (Baltimore). 2024. PMID: 38640313 Free PMC article.
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Dementia severity was assessed mainly through cognitive function, psychobehavioral symptoms, and daily living ability. ...Donepezil demonstrated superior binding t …
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Dementia severity was assessed …
Donepezil for dementia due to Alzheimer's disease.
Birks JS, Harvey R. Birks JS, et al. Cochrane Database Syst Rev. 2003;(3):CD001190. doi: 10.1002/14651858.CD001190. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. doi: 10.1002/14651858.CD001190.pub2. PMID: 12917900 Updated.
However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer. OBJECTIVES: The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due to …
However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer. OBJ …
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. Rogers SL, et al. Neurology. 1998 Jan;50(1):136-45. doi: 10.1212/wnl.50.1.136. Neurology. 1998. PMID: 9443470 Clinical Trial.
The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. ...The primary efficacy measures were the cognitive portion of the Alzheimer' …
The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) …
Donepezil for Alzheimer's disease.
Benjamin B, Burns A. Benjamin B, et al. Expert Rev Neurother. 2007 Oct;7(10):1243-9. doi: 10.1586/14737175.7.10.1243. Expert Rev Neurother. 2007. PMID: 17939763 Review.
Donepezil is the most widely prescribed of the cholinesterase inhibitors that has been licensed for the treatment of mild-to-moderate Alzheimer's disease. Evidence from a number of clinical trials suggests that it improves cognitive performance and sta …
Donepezil is the most widely prescribed of the cholinesterase inhibitors that has been licensed for the treatment of mild-to-moderate …
Lecanemab Questions.
Nadeau SE. Nadeau SE. Neurology. 2024 Apr 9;102(7):e209320. doi: 10.1212/WNL.0000000000209320. Epub 2024 Mar 14. Neurology. 2024. PMID: 38484213
The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. .. …
The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the p …
3,055 results